You searched for side effects - Page 25 of 311 - Medivizor
Navigation Menu

Analyzing the effectiveness and safety of abatacept for rheumatoid arthritis

Analyzing the effectiveness and safety of abatacept for rheumatoid arthritis

Posted by on Aug 27, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell The study investigated the effectiveness and safety of abatacept (Orencia) for patients with rheumatoid arthritis (RA). The analysis concluded that abatacept gave better results to patients with RA compared to other biologic drugs.  Some background RA is a common autoimmune disorder that affects the joints. This condition...

Read More

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Posted by on Aug 27, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of brentuximab vedotin (BV; Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the BV plus nivolumab combination...

Read More

Evaluating the effectiveness and safety of platelet rich plasma for the treatment of erectile dysfunction.

Evaluating the effectiveness and safety of platelet rich plasma for the treatment of erectile dysfunction.

Posted by on Aug 27, 2023 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness and safety of platelet-rich plasma (PRP) injections for the treatment of patients with mild and moderate erectile dysfunction (ED). The data showed that PRP was a safe and promising treatment for improving mild to moderate ED. Some background Erectile dysfunction (ED) consists of the inability to...

Read More

Evaluating the effectiveness and safety of Quisqualis indica extract for the treatment of patients with lower urinary tract symptoms.

Evaluating the effectiveness and safety of Quisqualis indica extract for the treatment of patients with lower urinary tract symptoms.

Posted by on Aug 27, 2023 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of Quisqualis indica (Rangoon creeper or Chinese honeysuckle; a type of plant) extract for the treatment of patients with lower urinary tract symptoms (LUTS). The data showed that Quisqualis indica extract was safe and effective for the treatment of these patients. Some background Benign...

Read More

Evaluating the long-term effectiveness and safety of fixed-duration combination of ibrutinib plus obinutuzumab-based immunochemotherapy for patients with chronic lymphocytic leukemia.

Evaluating the long-term effectiveness and safety of fixed-duration combination of ibrutinib plus obinutuzumab-based immunochemotherapy for patients with chronic lymphocytic leukemia.

Posted by on Aug 27, 2023 in Leukemia | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of the fixed-duration combination of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva)–based immunochemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The data showed that a fixed-duration combination of ibrutinib plus obinutuzumab-based...

Read More

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by on Jul 30, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (PV; Polivy) combined with dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The data showed that PV combined with dose-adjusted EPOCH-R...

Read More

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Evaluating the long-term effectiveness and safety of adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of patients with relapsed multiple myeloma.

Posted by on Jul 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that over the long term adding isatuximab to the Kd regimen was effective with manageable side...

Read More

Evaluating the long-term effectiveness and safety of nivolumab plus ipilimumab versus nivolumab alone after surgery in patients with stage IV melanoma.

Evaluating the long-term effectiveness and safety of nivolumab plus ipilimumab versus nivolumab alone after surgery in patients with stage IV melanoma.

Posted by on Jul 30, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab alone given after surgery in patients with stage IV melanoma. The data showed that both nivolumab plus ipilimumab and nivolumab alone after surgery were effective compared with placebo and significantly improved survival without...

Read More

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Posted by on Jul 2, 2023 in Hypertension | 0 comments

In a nutshell This study evaluated the effectiveness and safety of aprocitentan (ACT-132577) for lowering blood pressure (BP) in patients with resistant or uncontrolled hypertension (high BP). The data showed that aprocitentan was effective in lowering the BP after 4 weeks with a sustained effect after 40 weeks compared to a placebo with...

Read More

Evaluating the effectiveness and safety of indobufen plus clopidogrel versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention with drug-eluting stent.

Evaluating the effectiveness and safety of indobufen plus clopidogrel versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention with drug-eluting stent.

Posted by on Jul 2, 2023 in Coronary artery disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of indobufen (Ibustrin) plus clopidogrel (Plavix) versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES). The data showed that indobufen plus clopidogrel significantly reduced the risk of...

Read More

Evaluating the effectiveness and safety of mirabegron and solifenacin combination in patients with double-J stent related overactive bladder symptoms.

Evaluating the effectiveness and safety of mirabegron and solifenacin combination in patients with double-J stent related overactive bladder symptoms.

Posted by on Jul 2, 2023 in Overactive bladder | 0 comments

In a nutshell This study evaluated the effectiveness and safety of mirabegron (Myrbetriq) and solifenacin (Vesicare) combination in patients with double-J stent-related overactive bladder (OAB) symptoms. The study found that mirabegron and solifenacin combination significantly improved urinary symptoms, OAB symptoms, and the quality of life with...

Read More